Oxford BioMedica PLC (OXBDF)

[marcusl2]

How do you turn world-leading British science into medicines?
TELEGRAPH

Both the Government and industry will be hoping to replicate the UK’s early wins in gene therapy, a field now boasting 60 firms with £1bn investment behind them. Among them is Oxford BioMedica, a company that has developed a novel lentiviral delivery mechanism for modifying genes.

The AIM-listed firm’s market value has jumped by almost three quarters since June thanks to its partnership with Swiss conglomerate Novartis, which got provisional approval for a landmark gene therapy for leukaemia. All of Oxford BioMedica’s operations remain in Oxford.

“We have looked extensively at other countries,” John Dawson, its chief executive, says. “But we are happy with what we’ve got. We’ve had a very good run of being supported by government.” That support has included millions of pounds of research grants.

Keith Thompson, chief executive of the Cell & Gene Therapy Catapult, the Government body behind the Stevenage facility, says: “We’re hoping that when companies grow out of using the facility and need a bigger place, they’ll simply build it down the road.”

HTTP://www.telegraph.co.uk/business/2017/08/26/do-turn-world-leading-british-science-medicines/